Organisation paid for research Program year 2025 Source: CMS Open Payments

American Clinical Trials LLC

Neither a doctor nor a teaching hospital

Research payments

$1,797,490

145 payments

Through program year 2025, American Clinical Trials LLC is reported as receiving $1,797,490 in research payments, across 145 payments.

By program year

3 rows
Year Kind Amount Payments
2025 Research $1,420,240 99
2024 Research $346,818 42
2023 Research $30,432 4

Breakdown

Who paid Research payments · program years 2023–2025
  1. Eli Lilly and Company $1,027,231 10 payments
  2. CSL Behring $598,052 101 payments
  3. Hoffmann-La Roche Limited $129,939 33 payments
  4. Vertex Pharmaceuticals Incorporated $42,269 1 payment
Studies the money was for Research payments · program years 2023–2025
  1. A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis $598,052 101 payments
  2. A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(A) Who Have Established Atherosclerotic Cardiovascular Disease Or Are at Risk for A First Cardiovascular Event - Acclaim-Lp(A) $532,825 6 payments
  3. A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Event-Driven Study to Investigate the Effect of Retatrutide on the Incidence of Major Adverse Cardiovascular Events and the Decline in Kidney Function in Participants With Body Mass Index Greater Than 27 KG M2 and Atherosclerotic Cardiovascular Disease and Or Chronic Kidney Disease $494,406 4 payments
  4. Double blind study to determine efficacy of ASO Factor B in IgAN $129,939 33 payments
  5. A Phase 2/3 Adaptive, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of VX-147 in Subjects Aged 18 Years and Older With APOL1-mediated Proteinuric Kidney Disease $42,269 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record